The stock of Emerald Health Therapeutics Inc (CVE:EMH) hit a new 52-week high and has $2.23 target or 31.00% above today’s $1.70 share price. The 8 months bullish chart indicates low risk for the $152.92 million company. The 1-year high was reported on Nov, 16 by Barchart.com. If the $2.23 price target is reached, the company will be worth $47.41 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 1.59 million shares traded hands or 257.16% up from the average. Emerald Health Therapeutics Inc (CVE:EMH) has risen 6.00% since October 17, 2016 and is uptrending. It has outperformed by 1.31% the S&P500.
More news for Emerald Health Therapeutics Inc (CVE:EMH) were recently published by: Marketwatch.com, which released: “Emerald Health Therapeutics Completes Private Placement and Shares for Debt …” on September 21, 2016. Bloomberg.com‘s article titled: “Stemcentrx Sale to Return a Record $1.7 Billion for VC Firm Founders Fund” and published on April 28, 2016 is yet another important article.
Emerald Health Therapeutics, Inc., formerly T-Bird Pharma Inc., is a Canada company, which through its subsidiary, Emerald Health Botanicals Inc. , is engaged in the production and sale of medical marihuana. The company has a market cap of $152.92 million. The Company’s segment is production and sales of medical marihuana pursuant to the Marihuana for Medical Purposes Regulations. It currently has negative earnings. Botanicals produces cannabis oils and capsules.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.